| Revenue Growth | Pharma up 6%; Oncology/Multi-specialty up 24%; Prescription Tech up 10%. |
|---|---|
| Mgmt Confidence | High confidence; raised full-year guidance based on strong first-half momentum. |
| Demand Visibility | Strong GLP-1 demand ($16B revenue); stable utilization in oncology networks. |
| Margin Trends | Gross profit up 10% to $3.9B; operating profit up 13%. |
| Op. Leverage | Operating expenses as percentage of gross profit improved 141 basis points. |
| Pricing Power | Fairly compensated for distribution services; brand pricing decreases reduced revenue growth. |
| Vol vs Price | Growth driven by higher prescription volumes, especially specialty and GLP-1 medications. |
| Segment Growth | Oncology and Multi-specialty led growth; Med-Surgical solutions lagged with 5% growth. |
| New Clients | Extended CVS Health distribution relationship through June 2032. |
| Capex & Debt | Acquired Precision Medicine Group for $2.25B; $1.4B investment in Option Care. |
| Regulatory | Monitoring 340B policy changes and potential January 2027 rebate model implementation. |
| Commentary | Focusing on community-based care and biopharma services to drive long-term value. |
| New Launches | Launched Family Forward ERG; introduced medical prior authorization capabilities. |
Growth
Revenue grew 8% to $111B; adjusted EPS rose 18% to $11.68.
Outlook
Raised FY27 EPS guidance to $45.60-$46.40; targeting 13-16% long-term EPS growth.
Risks
Management was evasive on specific behavioral responses to potential 340B rebate model changes in 2027.
The company's earnings call, NYSE: MCK, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Mckesson Corp: key numbers
- Share price
- $1,105.04Close, Nov 16
- Market cap
- $128B
- Shares outstanding
- 115.46MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mckesson Corp
All →Mckesson EVP, CIO and CTO Francisco Fraga Sells $717K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 650 shares of Mckesson Corp at $1,102.96 a share, worth $717K in total on Nov 5, 2026. Shares held after the trade: 4,414 (-12.8%).
- Value
- $717K
- Shares
- 650
- Price
- $1,102.96
- Role
- EVP, CIO and CTO
- Holding change
- -12.8%
- Trade date
- Nov 5, 2026
Mckesson EVP, CIO and CTO Francisco Fraga Sells $630K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 600 shares of Mckesson Corp at $1,050.00 a share, worth $630K in total on Nov 4, 2026. Shares held after the trade: 5,064 (-10.6%).
- Value
- $630K
- Shares
- 600
- Price
- $1,050.00
- Role
- EVP, CIO and CTO
- Holding change
- -10.6%
- Trade date
- Nov 4, 2026
Mckesson Q2 2026 Results: Net Income $1.22B, Up 9.7% YoY
For the three months ended September 30, 2026, McKesson reported revenues of $111.0 billion, a 7.6% increase year-over-year, and net income attributable to the corporation of $1.2 billion. The company's balance sheet shows a significant increase in total assets to $92.3 billion, primarily driven by higher cash and inventory levels, while stockholders' deficit widened to $4.0 billion.
- Key figure
- Net income $1.22B · +9.7% YoY
Mckesson Financial Results
McKesson reported second quarter fiscal 2027 consolidated revenues of $111.0 billion, an 8% increase year-over-year, and raised its full-year adjusted EPS guidance. The results were driven by strong operational growth in the North American Pharmaceutical and Oncology & Multispecialty segments.
- Term
- Q2 2027
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.”
Brian Tyler, chair and chief executive officer
Mckesson EVP, CIO and CTO Francisco Fraga Sells $797K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 800 shares of Mckesson Corp at $995.80 a share, worth $797K in total on Oct 15, 2026. Shares held after the trade: 5,423 (-12.9%).
- Value
- $797K
- Shares
- 800
- Price
- $995.80
- Role
- EVP, CIO and CTO
- Holding change
- -12.9%
- Trade date
- Oct 15, 2026
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.
- Value
- $5.8B
- Counterparty
- Option Care Health, Inc.